Observational studyMedicine2026
The impact of chalazion after treatment on the morphology of the meibomian glands in children: An observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Morphological changes in the meibomian glands following treatment of pediatric chalazion were assessed using an ocular surface analyzer, and the effects of surgical versus conservative management on gland morphology were systematically compared.
methodsA total of 132 children with chalazion who had achieved complete recovery after treatment were selected as the research subjects and divided into 2 groups according to different treatment methods: the surgical treatment group (52 cases) and the drug treatment group (80 cases). Meanwhile, 40 asymptomatic healthy children during the same period were selected as the control group. The degree of meibomian gland loss was calculated and scored by using the ocular surface comprehensive analyzer.
resultThe meibomian gland loss score in the surgical group was (0.89 ± 0.96), in the drug treatment group it was (0.78 ± 0.61), and in the control group it was (0.40 ± 0.35). There was a significant difference in the score of meibomian gland loss between the chalazion group and the control group (P <.05). However, there was no significant difference in the degree of meibomian gland loss between surgical group and the drug group (P >.05).
conclusionChalazion can lead to meibomian gland loss, and changing the treatment method will not improve this situation. How to control the recurrence of chalazion is particularly important in preventing pediatric meibomian gland dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.